UK Regulator Updates SPC for Senvelgo Oral Solution in Cats, Narrows Indication and Strengthens Safety Warnings
核心洞察
The UK Veterinary Medicines Directorate (搜索) has updated the Summary of Product Characteristics for Senvelgo (搜索) 15 mg/ml Oral Solution for Cats following pharmacovigilance monitoring.
The indication has been narrowed to "reduction of hyperglycaemia in cats with non-insulin-dependent diabetes mellitus (搜索)," with additional patient selection guidance.
Vomiting has been reclassified as a common adverse event (1–10 per 100 animals), and diabetic ketoacidosis (搜索) now carries a "may be fatal" footnote.
The UK Veterinary Medicines Directorate (搜索) (VMD) has announced important updates to the Summary of Product Characteristics (SPC) for Senvelgo (搜索) 15 mg/ml Oral Solution for Cats, following routine monitoring of pharmacovigilance data. The changes, published on the UK Government website, include a narrowed therapeutic indication, enhanced patient selection guidance, and strengthened safety warnings regarding adverse events.
Indication Refined to Non-Insulin-Dependent Diabetes Mellitus (搜索)
The most significant update concerns the product's authorised indication, which has been revised to: "For the reduction of hyperglycaemia in cats with non-insulin-dependent diabetes mellitus (搜索)." This represents a more precise definition of the target patient population and underscores the importance of appropriate diagnosis before initiating treatment.
Additional information has been incorporated into section 3.5 of the SPC, "Special precautions for use," with particular emphasis on the selection of patients for treatment. While the VMD announcement does not detail the full content of these precautions, the update signals that clinicians should exercise careful diagnostic judgment when considering Senvelgo (搜索) therapy.
Adverse Event Profile Updated
The adverse events section (section 3.6) now lists vomiting under the common frequency category, defined as occurring in 1 to 10 animals per 100 animals treated. A footnote accompanying this entry states: "Vomiting is usually sporadic and resolves without specific therapy. Acute or more frequent vomiting may also be a sign of clinical Diabetic ketoacidosis (搜索) (DKA) or other severe disease conditions and should be investigated accordingly."
The entry for diabetic ketoacidosis (搜索) (DKA) has also been updated with a footnote that now explicitly warns: "May be fatal." This addition underscores the serious nature of this potential complication and the need for vigilant monitoring of treated cats.
Pharmacovigilance and Adverse Event Reporting
The VMD emphasised that no medicine is 100% risk-free and that the SPC serves as the definitive reference for known adverse events associated with a given product. The agency strongly encourages anyone aware of an adverse event to report it to either the Marketing Authorisation Holder (MAH) or directly to the VMD.
Contact details for the relevant MAH can be found on the product leaflet, via the Product Information Database, or on the MAH's website. Reports can be submitted directly to the VMD through the official "Report a suspected problem with an animal medicine" portal on GOV.UK. The VMD noted that reporting to both the MAH and the VMD may create duplicate reports, which affects the efficiency of data handling and the quality of the information held.
The VMD reiterated that the reporting of adverse events is critical to ongoing monitoring activities designed to protect animal health, public health, and the environment.